Evidence map›Paper›PMID 37240048›Full record

Observational studyInternational journal of molecular sciences2023

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis.

Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Salvador Arias-Santiago, Antonio Giovanni Richetta, Laura Ottini, Laura Elena Pineda-Lancheros, Maria Del Carmen Ramírez-Tortosa, Alberto Jiménez-Morales

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Cristina Membrive-JiménezPharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avenida. de las Fuerzas Armadas 2, 18004 Granada, Spain.
Cristina Pérez-RamírezDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Campus Universitario de Cartuja, University of Granada, 18011 Granada, Spain.
Salvador Arias-SantiagoDermatology Service, University Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0000-0002-4186-1435
Antonio Giovanni RichettaUnit of Dermatology, Department of Internal Medicine and Medical Specialties Sapienza, University of Rome, 00161 Rome, Italy.
Laura OttiniDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0001-8030-0449
Laura Elena Pineda-LancherosPharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avenida. de las Fuerzas Armadas 2, 18004 Granada, Spain.ORCID 0000-0002-5111-3895
Maria Del Carmen Ramírez-TortosaDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Campus Universitario de Cartuja, University of Granada, 18011 Granada, Spain.ORCID 0000-0002-7999-0881
Alberto Jiménez-MoralesPharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avenida. de las Fuerzas Armadas 2, 18004 Granada, Spain.
Hospital Universitario Virgen de las Nieves · ESSapienza University of Rome · ITUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological therapies (BTs) indicated for psoriasis are highly effective; however, not all patients obtain good results, and loss of effectiveness is the main reason for switching. Genetic factors may be involved. The objective of this study was to evaluate the influence of single-nucleotide polymorphisms (SNPs) on the drug survival of tumor necrosis factor inhibitors (anti-TNF) medications and ustekinumab (UTK) in patients diagnosed with moderate-to-severe psoriasis. We conducted an ambispective observational cohort study that included 379 lines of treatment with anti-TNF (

Indexed as

Organic Anion TransportersPsoriasisAdalimumabBiological TherapyHLA-C AntigensHumansInfliximabQuality of LifeSignaling Lymphocytic Activation Molecule FamilyToll-Like Receptor 5Tumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumabAdalimumabCD84 protein, humanHLA-C AntigensInfliximabOrganic Anion TransportersSignaling Lymphocytic Activation Molecule FamilySLCO1C1 protein, humanToll-Like Receptor 5Tumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumabadalimumabanti-TNFCD84etanerceptHLA-CinfliximabPDE3ATLR5TNF-1031ustekinumab

Identifiers

PMID37240048
PMCPMC10218224
OpenAlexW4376614842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.